Key clinical point: Long-term data suggests allogeneic hematopoietic cell transplantation (allo-HCT) and autologous hematopoietic cell transplantation (auto-HCT) are both viable consolidation treatment options for patients with mantle cell lymphoma (MCL).
Major finding: After a median follow up of 13.6 years, the 1- and 5-year OS for allo-HCT and auto-HCT were 62.2% and 39.3%, respectively; and 74.3% and 53.7%, respectively.
Study details: A retrospective analysis of 53 patients with MCL who underwent either allo- or auto-HCT.
Disclosures: No funding sources were reported. No conflicts of interest were reported.
Naik S et al. Biol Blood Marrow Transplant. 2020 Jan 23. doi: 10.1016/j.bbmt.2019.12.496.